Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...

Murdo Gordon, Executive Vice President of Global Commercial Operations at Amgen Inc . (NASDAQ:AMGN), recently sold a significant portion of the company's stock. According to a filing with the ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Companies on the 2024 Inc. 5000 are ranked according to percentage revenue growth over the last three years. They generated 874,940 jobs, $317 billion in revenue, and show where the economy is going.